Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 7/20 | 0.49 |
| ▸ | ITGAV | P06756 | 7/20 | 0.49 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 10/20 | 0.45 |
| ▸ | MC5R | P33032 | 10/20 | 0.45 |
| ▸ | MC3R | P41968 | 10/20 | 0.45 |
| ▸ | MC1R | Q01726 | 10/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.45 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19595173 | 0.94 | ITGB3 (0.49) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL16920496 | 0.93 | ITGB3 (0.59) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL22594705 | 0.93 | ITGB3 (0.59) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL451423 | 0.93 | ITGB3 (0.59) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL12468724 | 0.91 | ITGB3 (0.47) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL16923811 | 0.91 | ITGB3 (0.52) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL24202406 | 0.89 | ITGB3 (0.48) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL22807659 | 0.89 | ITGB3 (0.48) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL16920494 | 0.86 | ITGB3 (0.51) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL27360546 | 0.86 | ITGB3 (0.49) | ITGB3ITGAVITGB5ITGA2BITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110182989-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CELLULAR ADHESION OR DIRECTING DIAGNOSTIC OR THERAPEUTIC AGENTS TO RGD BINDING SITES | ALLEGRO PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182989-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CELLULAR ADHESION OR DIRECTING DIAGNOSTIC OR THERAPEUTIC AGENTS TO RGD BINDING SITES | HGFAC, ARGLU1, CCR3 | ITGB3 4/4885ITGAV 103/4885ITGB5 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.